# Oral Semaglutide vs DPP-4 Inhibitors and Cognitive Impairment in HFpEF | This GLP In 246 elderly HFpEF patients with obesity and type 2 diabetes, 33 new cases of cognitive impairment on oral semaglutide against 73 on DPP-4 inhibitors, a result a larger US study did not reproduce. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/oral-semaglutide-cognitive-impairment Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Oral Semaglutide vs DPP-4 Inhibitors and Cognitive Impairment in HFpEF In 246 elderly patients with heart failure, obesity and type 2 diabetes, new cognitive impairment was 77% lower on oral semaglutide. A 13,007-patient study of the same comparison found no difference. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 New cognitive impairment over one year · oral semaglutide · 33 cases · 26.8 per 100 patient-years · DPP-4 inhibitor · 73 cases · 59.3 per 100 patient-years · 106 of 246 people, in twelve months. p < 0.0001. · A larger study of the same comparison found no difference. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 246 elderly outpatients with heart failure, obesity and type 2 diabetes, on oral semaglutide or a DPP-4 inhibitor. - Over one year, 106 developed cognitive impairment — 33 on semaglutide against 73 on the comparator, p < 0.0001. - A logistic regression put the reduction at 77%. No confidence interval is published in the abstract. - That is 43.1 new cases per 100 patients per year across the whole cohort. - A larger study of the same drug against sitagliptin, also a DPP-4 inhibitor, found no significant difference. This is the largest effect on cognition anybody has reported for these drugs, and it points the opposite way from the other study in this section that ran the same comparison. Both cannot be describing the same reality, and working out why is more useful than either number. ## What this study found Elderly outpatients with heart failure with preserved ejection fraction, obesity and type 2 diabetes were given oral semaglutide or a DPP-4 inhibitor as an add-on, matched on age, sex and body mass index, and followed a year. [\[1\]](https://thisglp.com/research/oral-semaglutide-cognitive-impairment#ref-1) New cognitive impairment appeared in 33 of the semaglutide group and 73 of the comparator group, p < 0.0001, which a logistic regression rendered as a 77% lower risk. The abstract publishes that 77% without a confidence interval, so how precisely it is estimated cannot be read off the record. The other study, and what separates them A US study of 13,007 patients compared semaglutide against sitagliptin — a DPP-4 inhibitor — and found [no significant difference on cognitive signs](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs). The comparison is the same; almost nothing else is. That study scored signs recorded in routine notes across a psychiatric population; this one counted formally incident cognitive impairment in a cardiology clinic. Different outcome, different ascertainment, different patients — and a 77% reduction against a null is too large a gap for both to be measuring one thing. ## The incidence is the tell 106 new cases among 246 people in twelve months, or 43.1 per 100 patients per year. Nearly half the cohort acquired a cognitive impairment diagnosis inside a year. That is far above what a general elderly population would produce, which means either the population was already close to the threshold or the threshold was set low. Neither is wrong — a cardiology clinic full of elderly patients with heart failure, obesity and diabetes is a high-risk group — but it does mean the outcome being counted here is not the outcome most readers picture, in the same way [an entry criterion set locally](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) changes what a trial is about. ## What the matching covers Age, sex and body mass index. Those are the three variables the abstract names. The strongest predictors of a new cognitive impairment diagnosis are baseline cognition and education, and neither appears in that list. In a non-randomized comparison where a clinician chose who got which drug, that gap matters — it is the same structural weakness as every [real-world comparison assembled after the fact](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## How to hold both results As an open question, not a settled benefit. One study found a very large effect in a small, high-risk, narrowly matched cohort; a much larger one found nothing against the closest available comparator. Nobody is selling these drugs for cognition and nothing here is a reason to buy one. What the pair demonstrates is that a single striking percentage is worth very little until somebody has asked what else was published on the same question — the habit [reading any body of literature](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) requires. ## Frequently asked Does semaglutide protect against cognitive decline? This study found 33 new cases against 73 over a year, a 77% lower risk. A much larger study comparing semaglutide with sitagliptin found no significant difference, so the question is open. Why is the incidence so high? 106 cases among 246 people in a year is 43.1 per 100 patient-years. That reflects a high-risk cardiology population, a low diagnostic threshold, or both. How precise is the 77%? Unknown from the published abstract, which reports the point estimate from a logistic regression without a confidence interval. Were the groups comparable? They were matched on age, sex and body mass index. Baseline cognition and education — the strongest predictors of a new diagnosis — are not among the matching variables named. ## Sources 1. \[1\] Armentaro G, et al. (2026). Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity Internal and Emergency Medicine. [PMID 42622752](https://pubmed.ncbi.nlm.nih.gov/42622752/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)